Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone

Autor:	Rodney H. Falk, Jessica Laird, Melissa L Coyle, Sarah Cuddy
Rok vydání:	2020
Předmět:	0301 basic medicine Tafamidis medicine.medical_specialty Atorvastatin AST aspartate aminotransferase 030105 genetics & heredity Amiodarone 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine ALT alanine aminotransferase Internal medicine medicine CK creatinine kinase Diseases of the circulatory (Cardiovascular) system restrictive CYP3A4 cytochrome P-450 3A4 pathway ATTR transthyretin amyloidosis biology LFT liver function test business.industry nutritional and metabolic diseases Mini-Focus Issue: Heart Failure medicine.disease Transthyretin chemistry Cardiac amyloidosis RC666-701 Concomitant Cardiology biology.protein Creatine kinase Case Report: Clinical Case atherosclerosis BCRP breast cancer receptor protein Cardiology and Cardiovascular Medicine business cardiomyopathy Rhabdomyolysis 030217 neurology & neurosurgery medicine.drug
Zdroj:	JACC: Case Reports, Vol 2, Iss 15, Pp 2372-2375 (2020) JACC Case Reports
ISSN:	2666-0849
DOI:	10.1016/j.jaccas.2020.09.037
Popis:	An 85-year-old women with transthyretin cardiac amyloidosis presented with generalized weakness, elevated liver function test levels, and creatinine kinase consistent with rhabdomyolysis 1 week after starting tafamidis. She was already taking atorvastatin and amiodarone, raising the possibility of a drug–drug interaction inhibiting the breakdown and excretion of atorvastatin, causing drug-induced rhabdomyolysis. (Level of Difficulty: Intermediate.) Graphical abstract
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a34ac87cd304bacd2b5e423896bf143 https://doi.org/10.1016/j.jaccas.2020.09.037 Zobrazit plný text záznamu